Syndeio Biosciences is a clinical-stage neurology company developing precision CNS therapies centered on the synapse as a target.

Syndeio’s focus is on creating a new class of CNS drugs by targeting synaptic structure, function and plasticity across psychiatric, cognitive, and neurodegenerative diseases. The company is advancing a deep pipeline of assets through clinical trials and R&D programs. Defining Syndeio’s innovative approach to CNS drug development is the Boost™ predictive model which is built on the work of Nobel Prize winner and Catalio Venture Parter, Dr. Tom Südhof. This model provides proprietary translational insights by integrating clinical, pharmacologic, and biomarker data to inform synapse-enhancing dosing parameters and successfully predict positive and negative clinical outcomes.

‍